Accurate information about the effects of donor nephrectomy is important in counseling potential live kidney donors. Issues involve both the short-term risk – the risks of surgery and the immediate peri-operative period – and the long-term risks – overall health and specifically the function of the remaining kidney. Review of peri-operative mortality and long-term survival from registry data in over 80,000 live kidney donors from 1994 through 2009 revealed an overall 90 day mortality rate of 3.1 per 10,000 live donor nephrectomies. Surgical mortality was higher in men than women (5.1 vs. 1.7 per 10,000) and in African American/Hispanic compared with white donors (7.6 vs 2.6 per 10,000). Neither increased donor age, smoking, nor obesity (BMI > 30) was associated with higher surgical mortality. The long-term survival of living kidney donors was no different than that of age- and co-morbidity-matched National Health and Nutrition Examination Survey participants for all patients stratifies by age, sex, and race. Obesity is a common issue in potential live donors: a review of the OPTN database of over 5,000 live donors with known BMI data who donated over a 1.5 year period between July 2004 and December 2005 revealed that 40% were overweight, 17.8% were obese (BMI 30-35) and 4.7% were very obese (BMI >35). At baseline and at 6 month follow-up, higher BMI was associated with higher systolic BP, but changes in BP were similar across the groups. There were no apparent differences in decline in GFR or percent change in serum creatinine across these categories of obesity in 6 month follow-up. Others studies have shown that there is no greater decline in renal function in obese patients compared with non-obese patients. Lifetime risk of requiring renal replacement therapy after kidney donation is less than 1%.
Tavakol, MM, Vincenti, FG, Assadi, H, Frederick, MJ, Tomlanovich, SJ, Roberts, JP, Posselt, AM:
Long-term renal function and cardiovascular disease risk in obese kidney donors. Clin J Am Soc
Nephrol 4:1230-8, 2009
Nogueira, JM, Weir, MR, Jacobs, S, Breault, D, Klassen, D, Evans, DA, Bartlett, ST, Cooper, M: A study
of renal outcomes in obese living kidney donors. Transplantation 90:993-9, 2010
Reese, PP, Feldman, HI, Asch, DA, Thomasson, A, Shults, J, Bloom, RD: Short-term outcomes for
obese live kidney donors and their recipients. Transplantation 88:662-71, 2009
Axelrod, DA, McCullough, KP, Brewer, ED, Becker, BN, Segev, DL & Rao, PS: Kidney and pancreas
transplantation in the United States, 1999-2008: the changing face of living donation. Am J Transplant
10:987-1002, 2010
Davis, CL, Cooper, M: The state of U.S. living kidney donors. Clin J Am Soc Nephrol 5:1873-80, 2010
Segev, DL, Muzaale, AD, Caffo, BS, Mehta, SH, Singer, AL, Taranto, SE, McBride, MA, Montgomery,
RA: Perioperative mortality and long-term survival following live kidney donation. JAMA 303:959-66, 2010
Lentine, KL, Schnitzler, MA, Xiao, H, Saab, G, Salvalaggio, PR, Axelrod, D, Davis, CL, Abbott, KC,
Brennan, DC: Racial variation in medical outcomes among living kidney donors. N Engl J Med
363:724-32, 2010
Ardavan Mashhadian D.O.
Nephrologist
1400 S Grand Ave Suite 615, Los Angeles, CA 90015
(213) 537-0328
Since starting my training in the field of nephrology, my biggest dream has been to see my patients independent of dialysis and having a normal life. Kidney represents the human organ in highest demand among 120,000 U.S. patients waiting for organ donations.
The usual and most frequent source of kidneys for transplantation has been donation before cardiac death, formerly known as the heart-beating cadaveric donor. The increasing worldwide discrepancy between the availability and need for renal allografts has led to the increasing use of alternative sources of organs, including donation after cardiac death and live donors.
Approximately 18 people die every day waiting for an organ transplant. But that may change someday sooner than you think -- thanks to 3D printing.
Over a year ago, I started this blog when I saw printing human kidney shown on TED.com.Like other forms of 3D printing, bio-printing lays down layer after layer of live cells to form a solid human tissue. The major stumbling block in creating tissue continues to be manufacturing the vascular system needed to provide it with life-sustaining oxygen and nutrients.
Researchers hope that new generations of 3D printers can use living human cells to build replacement organs — especially organs such as livers, hearts and kidneys.
A 3D-printed kidney, like other 3D-printed replacement organs, likely won't become a reality within the next 10 or 15 years, researchers say. But they plan to use the simplified, miniature versions of 3D-printed organs created so far as guinea pigs for pharmaceutical drug testing — an idea that could help scientists to discover drugs suitable for humans more efficiently and ethically than animal testing.
Currently, there are about 120,000 people on the organ waiting list in the U.S., and even those who receive a donated organ face the prospect of ongoing medical challenges because of organ rejection issues. However, if a patient's own stem cells could be used to regenerate a living organ, rejection would become moot.
To date, the researchers have been able to create a piece of tissue the size of a thumbnail and keep it alive for two weeks.
What do you guys think about this technology? Could this be a reality or a science fiction?
Ardavan Mashhadian D.O.
Nephrologist
1400 S Grand Ave Suite 615, Los Angeles, CA 90015
(213) 537-0328
People with chronic kidney disease (CKD) have high risk of developing heart disease and dying prematurely. Although heart disease has many causes, damage caused by poor oxygen exchange in the body’scells (oxidative stress) is thought to be a major problem.
People withCKD often have evidence of oxidative stress and this is positively associated with the rate of kidney disease progression. A cochrane systemic review assessed how antioxidant therapy influenced outcomes for patients with CKD. Overall, we found that antioxidant therapy did not reduce the risk of heart disease or death in people with CKD, but that this could vary depending on CKD stage.
There was some evidence to suggest that people on dialysis may benefit from antioxidant treatment, and that these therapies could reduce the risk of kidney disease becoming worse. However, these results are based on very limited evidence and further studies are needed to confirm if antioxidant therapy could be of benefit for people with CKD.
Ardavan Mashhadian D.O.
Nephrologist
1400 S Grand Ave Suite 615, Los Angeles, CA 90015
(213) 537-0328
Control of hypertension is the single most important intervention to delay progression of chronic kidney disease (CKD). Extracellular fluid volume expansion is one of the most important factors leading to persistent hypertension in patients with CKD. Older individuals and black patients are more likely to be salt-sensitive and exhibit an antihypertensive response to sodium restriction or diuretic therapy.
If hypertension and proteinuria persist despite sodium restriction, the addition of a diuretic may be beneficial. Thiazide diuretics, if not used as a first-choice antihypertensive drug, are almost always indicated as an additional drug in patients with incompletely controlled hypertension, because these agents augment most other agents used as monotherapy.
Most hypertensive patients will require more than one antihypertensive drug to lower BP below target levels. The combination of diuretics with renin-angiotensin system (RAS) antagonists offers several advantages to include additive BP-lowering efficacy and enhanced reductions in urinary protein excretion. Thiazide diuretics are associated with metabolic complications that are particularly evident when used in high doses. When used in combination with RAS blockade, metabolic complications such as hypokalemia are minimized. The avoidance of hypokalemia has been linked to less thiazide-induced glucose intolerance. Patient persistence on therapy is dependent on well tolerated drug combinations.
Ardavan Mashhadian D.O.
Nephrologist
1400 S Grand Ave Suite 615, Los Angeles, CA 90015
(213) 537-0328
Resistant hypertension is defined as blood pressure that remains above goal despite treatment with the optimal dosage of three antihypertensive agents, including a diuretic.
Patient characteristics more likely to be associated with resistant hypertension include:
1. Older age
2. BMI above 30
3. Higher baseline blood pressure
4. Diabetes mellitus
5. Black race.
Excessive consumption of dietary salt and alcohol contributes to resistant hypertension. Many patients with resistant hypertension have secondary hypertension caused by primary aldosteronism or renovascular hypertension, and these conditions should be excluded.
Treatment of resistant hypertension should include appropriate lifestyle modifications, discontinuation of agents that may increase blood pressure such as NSAIDs, and correction of secondary causes of hypertension. Mineralocorticoid receptor antagonists are particularly effective in treating resistant hypertension even in the absence of hyperaldosteronism. The Anglo-Scandinavian Cardiac Outcomes Trial evaluated the efficacy of spironolactone among 1411 participants with an average age of 63 years who received this medication mainly as a fourth-line antihypertensive agent for uncontrolled blood pressure. After 1 year of treatment, blood pressure in these patients decreased by approximately 21.9/9.5 mm Hg.
Ardavan Mashhadian D.O.
Nephrologist
1400 S Grand Ave Suite 615, Los Angeles, CA 90015
(213) 537-0328
Lifestyle modifications are recommended for all patients with hypertension, including prehypertension. The Dietary Approaches to Stop Hypertension (DASH) study showed that 8 weeks of a diet of fruits, vegetables, low-fat dairy products, whole grains, poultry, fish, and nuts, along with a reduction in fats, red meat, and sweets, caused an 11.4-mm Hg decrease in systolic pressure and a 5.5-mm Hg decrease in diastolic pressure. In addition, patients using the DASH diet who consumed less than 100 mmol/d of sodium had a systolic pressure 3 mm Hg and a diastolic pressure 1.6 mm Hg less than those who consumed high amounts of sodium.
Weight reduction in a patient whose weight is 10% above ideal body weight lowers blood pressure by an average of 5 to 7 mm Hg. Alcohol consumption should be limited to two drinks daily for men and one for women, because excess amounts of alcohol may contribute to hypertension and resistance to antihypertensive medications. Regular aerobic exercise also modestly decreases blood pressure. In addition, patients should be counseled about smoking cessation.
The goal of treatment of hypertension is to reduce cardiovascular morbidity and mortality by lowering blood pressure. Lowering blood pressure has definitively been shown to reduce stroke, myocardial infarction, heart failure, and overall cardiovascular mortality. Evidence obtained from clinical trials suggests that the goal of antihypertensive treatment is to reduce blood pressure to below 140/90 mm Hg in the general population. The American Heart Association recommends a blood pressure target of 130/80 mm Hg for those with coronary artery disease, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm, and a Framingham 10-year risk score of 10% or greater. However, data clearly demonstrate a linear, progressive increased risk of ischemic heart disease and stroke in patients with blood pressures higher than 115/75 mm Hg, which suggests that these targets may be too high. Clinical trials addressing lower blood pressure targets are currently being planned.
Ardavan Mashhadian D.O.
Nephrologist
1400 S Grand Ave Suite 615, Los Angeles, CA 90015
(213) 537-0328
